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Chronic obstructive pulmonary disease (COPD) is a com-mon, complex condition that is a worldwide leading 
cause of death, disability, and poor health.1 Although primar-
ily a lung disease, extrapulmonary manifestations contribute to 
poor health and are associated with increased risk of mortality 
and hospitalization.2 Cardiovascular disease (CVD) is one of 
the most common comorbidities observed in COPD. Indeed, a 
third of all deaths in patients with COPD are from CVD, and 
patients with COPD have 2× to 5× increased risk of CVD com-
pared with the general population.3,4 Whether shared risk fac-
tors, such as smoking, fully explain the association is currently 
unclear. Therefore, a better understanding of cardiovascular 
risk in patients with COPD and the underlying mechanisms is 
needed to improve clinical outcomes.
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Abstract—Cardiovascular disease is a common comorbidity and cause of mortality in chronic obstructive pulmonary 
disease. A better understanding of mechanisms of cardiovascular risk in chronic obstructive pulmonary disease patients 
is needed to improve clinical outcomes. We hypothesized that such patients have increased arterial stiffness, wave 
reflections, and subclinical atherosclerosis compared with controls and that these findings would be independent of 
smoking status and other confounding factors. A total of 458 patients with a diagnosis of chronic obstructive pulmonary 
disease and 1657 controls (43% were current or ex-smokers) with no airflow limitation were matched for age, sex, and 
body mass index. All individuals underwent assessments of carotid–femoral (aortic) pulse wave velocity, augmentation 
index, and carotid intima–media thickness. The mean age of the cohort was 67±8 years and 58% were men. Patients 
with chronic obstructive pulmonary disease had increased aortic pulse wave velocity (9.95±2.54 versus 9.27±2.41 m/s; 
P<0.001), augmentation index (28±10% versus 25±10%; P<0.001), and carotid intima–media thickness (0.83±0.19 
versus 0.74±0.14 mm; P<0.001) compared with controls. Chronic obstructive pulmonary disease was associated 
with increased levels of each vascular biomarker independently of physiological confounders, smoking, and other 
cardiovascular risk factors. In this large case-controlled study, chronic obstructive pulmonary disease was associated with 
increased arterial stiffness, wave reflections, and subclinical atherosclerosis, independently of traditional cardiovascular 
risk factors. These findings suggest that the cardiovascular burden observed in this condition may be mediated through 
these mechanisms and supports the concept that chronic obstructive pulmonary disease is an independent risk factor 
for cardiovascular disease.  (Hypertension. 2018;71:499-506. DOI: 10.1161/HYPERTENSIONAHA.117.10151.) 
• Online Data Supplement
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Previous studies have reported inconsistent data on sur-
rogate biomarkers of cardiovascular risk observed in patients 
with COPD. A major source of variation between studies is 
how cardiovascular risk is evaluated, inherent differences 
between populations, variable adjustment for confounders, 
and small sample sizes.5 Several small studies have examined 
aortic pulse wave velocity (aPWV), the gold standard measure 
of arterial stiffness and an independent predictor of cardio-
vascular events and mortality in the general population,6 and 
consistently report elevated aPWV in patients with COPD.7 
However, it is less clear whether this association is simply 
related to smoking. In contrast, in the Copenhagen Heart 
Study, augmentation index (AIx), a composite measure of 
arterial wave reflections and arterial stiffness, was increased 
in subjects with airflow obstruction, but this was considered 
to be because of smoking and not a direct complication of 
COPD.8 Fewer studies have examined carotid intima–media 
thickness (CIMT), a marker of subclinical atherosclerosis, in 
COPD, although 1 study reported smokers with mild airflow 
limitation to have increased CIMT compared with smokers 
without airflow limitation.9 However, as far as we are aware, 
comprehensive assessments of these vascular biomarkers have 
not previously been undertaken in the same group of patients 
with COPD or with appropriate adjustment for confounding 
variables.
We hypothesized that patients with COPD compared with 
age-, sex-, and body mass index (BMI)–matched controls 
have elevated arterial stiffness, increased wave reflections, and 
increased subclinical atherosclerosis, independently of smok-
ing and other confounding factors. We also sought to evaluate 
both the impact of smoking and presence of COPD per se on 
these vascular biomarkers and the relationship between these 
vascular biomarkers and COPD severity.10
Methods
Data and analysis methods that support the findings of this study 
are available from the corresponding author on reasonable requests. 
Study materials and methods used to conduct the study are described 
in detail below. ERICA (Evaluation of the Role of Inflammation in 
Chronic Airways disease) is a prospective, observational study of 
patients with COPD recruited from 5 UK centers.11 The study was 
approved by the Cambridge South Research Ethics Committee (REC: 
11/EE/0357), and all participants provided written informed consent. 
The study was performed in accordance with institutional guidelines 
and in accordance with the Declaration of Helsinki. For this analy-
sis, we included data from patients with COPD recruited from the 
Cambridge and Cardiff study sites only because controls from the 
ACCT (Anglo Cardiff Collaborative Trial) had also been studied at 
both sites. Expanded methods are provided in the online-only Data 
Supplement.
Patients With COPD
Patients were aged ≥40 years, with ≥10 pack years smoking history, a 
clinical diagnosis of COPD, and postbronchodilator forced expiratory 
lung volume in 1 second <80% and forced expiratory lung volume 
in 1 second/forced vital capacity ratio <0.7. Patients had to be clini-
cally stable and free of exacerbations in the preceding 4 weeks before 
enrollment in the study.
Control Subjects
Controls were selected in a frequency-matched manner from an 
anonymized database of the ACCT study12 to provide 3 age-, sex-, 
and BMI-matched controls for every ERICA patient with COPD 
using bands of continuous variables of age and BMI. Only sub-
jects with smoking status recorded were included in the analysis, 
and subjects with a diagnosis of COPD, or spirometry that would 
support a diagnosis of COPD (forced expiratory lung volume in 1 
second/forced vital capacity <0.7), were excluded. Besides these 
demographics, all other variables were unselected and blinded dur-
ing the matching process, including all hemodynamic data, vascu-
lar biomarkers of interest, cardiovascular risk factors, CVD, and 
other disease history.
Vascular Biomarkers and Laboratory Assessments
In all individuals, blood pressure was recorded after 15 minutes 
of seated rest using a validated osillometric device (HEM 750CP; 
Omron Corporation, Japan). Radial artery waveforms were 
then recorded using a high fidelity micromanometer (SPC-301; 
Millar Instruments) and SphygmoCor software (AtCor Medical, 
Australia), which generated a corresponding central (ascending 
aortic) pressure waveform, using a validated transfer function.13 
From this, the AIx, a measure of wave reflections, was calculated. 
After a further period of supine rest, blood pressure was reassessed 
and then carotid–femoral aPWV, a measure of aortic stiffness, cal-
culated using the SphygmoCor device by sequential recording of 
ECG-gated pressure waveforms at the carotid and femoral sites, 
as previously described, with surface distances measured using a 
tape measure.14
High-resolution B-mode ultrasound was used to determine CIMT 
of the common carotid arteries, measured 1 cm from the bulb. Image 
analysis was performed using Vascular Tools 5 software (Medical 
Imaging Application PLC), with the larger of the 2 values (left or 
right) used in analysis. CIMT measurement was available for only a 
limited number of controls (n=279). Further information on assess-
ments is provided in the online-only Data Supplement.
COPD Severity
Patients with COPD were classified into quartiles of the BODE Index 
(BMI [B], degree of airflow obstruction [O], and functional dyspnea 
[D], and exercise capacity [E] as assessed by the 6-minute walk test). 
score,10 which is a multidimensional tool of COPD severity, that pre-
dicts mortality in COPD (see online-only Data Supplement). Vascular 
biomarkers were compared across quartiles. In addition, the relation-
ship of exacerbations with vascular biomarkers was examined.
Statistical Analysis
Study size was calculated to obtain at least 3 control subjects for 
every patient with COPD to allow precise quantification of any 
potential differences in patients with COPD versus controls. This 
approach was undertaken because previous smaller case-con-
trolled studies have assessed only 1 vascular biomarker using a 1:1 
approach and often not adjusted for physiological confounders.7 
Data were analyzed using SPSS (v23), and a P<0.05 was deemed 
significant for statistical analyses. Student t test, χ2 test and gen-
eral linear models with covariates were used to evaluate differences 
between groups, with adjustment for study site performed in all 
analyses, and adjustments made for known physiological confound-
ers of vascular biomarkers if statistically different between groups. 
For aPWV, adjustments for heart rate, mean arterial pressure, age, 
sex, and BMI were made if required. For AIx, adjustments for 
heart rate, age, sex, and height, and for CIMT, adjustments for age 
and systolic blood pressure were similarly performed if required. 
To determine the impact of smoking, we evaluated vascular bio-
markers stratified by smoking status within each subject group and 
compared patients with COPD to specifically current smoking/ex-
smoker controls. To determine whether COPD was associated with 
each vascular biomarker, data from patients and controls were com-
bined, and COPD diagnosis (yes/no) binary coded and included as 
an independent variable in regression analyses. Furthermore, odds 
ratios were calculated for aPWV >10 m/s and CIMT >0.90 mm, as 
thresholds defined for increased vascular risk,15 adjusted for vari-
ables associated with each vascular biomarker. Data are expressed 
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as means±SD or percentages. Bar graphs represent mean values, 
and error bars represent 95% confidence intervals.
Results
The demographic characteristics of the patients with COPD 
and controls are shown in Table 1. Data from 2115 subjects 
(458 patients, 1657 controls) were available. There were 
no differences between the patients and controls for age, 
sex, or BMI. As expected, the proportion of current and ex-
smokers in the COPD group versus controls was significantly 
higher (P<0.001). A total of 18 (3.9%) patients with COPD 
used supplementary oxygen. Cardiovascular comorbidity 
was increased in patients compared with controls. Use of 
antihypertensive therapy was similar between groups, but 
more patients with COPD were taking cholesterol-reducing 
treatments (P<0.001 versus controls).
Vascular Biomarkers
Data are summarized in Table 2. Systolic blood pressure 
and heart rate were higher in patients with COPD compared 
with controls (P<0.001 for both). In addition, aPWV, AIx, 
and CIMT were all higher in patients with COPD, even after 
adjustment for confounders (P<0.001 for all; Figure). Similar 
trends were observed when patients with COPD were com-
pared with control smokers/ex-smokers only (Table 3) and 
when individuals from both groups without known cardio-
vascular comorbidity were compared (Table S1 in the online-
only Data Supplement). Analysis of AIx in subjects aged ≤55 
years was performed because age-related changes in AIx are 
more prominent in younger individuals, and AIx is known 
to plateau after 55 years of age.12,16 This showed a mean dif-
ference of +10% AIx in patients with COPD versus controls 
(25±11% versus 15±10%; P<0.001), adjusted for heart rate, 
height, and study site. In contrast, above this age cutoff and in 
the whole-study data set, smaller +3% differences (P<0.001 
for both) in AIx were observed between patients with COPD 
and controls.
Impact of Smoking
Table S2 shows demographic and vascular biomarkers strati-
fied by smoking status in patients with COPD and controls. 
There were no significant differences in aPWV or AIx in con-
trols when stratified by smoking status. The small number of 
CIMT measurements in controls did not permit a subanalysis 
of CIMT by smoking status. In patients with COPD, AIx was 
elevated in current versus ex-smokers, but both COPD current 
Table 1. Demographic Characteristics of Patients With COPD 
and Controls
Variable
COPD
 n=458
Controls
 n=1657 P Value
Age, y 67±8 67±8 0.9
Male, n (%) 264 (58%) 978 (59%) 0.3
Body mass index, kg/m2 27.68±5.70 27.36±4.33 0.2
Current smoker, n (%) 151 (33%) 71 (4%) <0.001
Ex-smoker, n (%) 307 (67%) 647 (39%) <0.001
Never smoker, n (%) 0 939 (57%) <0.001
Spirometry
  FEV
1
, L 1.33±0.53 2.49±0.84 <0.001
  FEV
1
 % predicted 53±16 100±18 <0.001
  FVC, L 2.68±0.88 3.09±0.94 <0.001
  FVC % predicted 85±20 96±18 <0.001
  FEV1/FVC 0.50±0.12 0.85±0.73 <0.001
Cardiovascular medical history
  Angina (%) 11 4 <0.001
  Myocardial infarction (%) 8 2 <0.001
  Stroke (%) 8 4 <0.001
  Diabetes mellitus (%) 14 3 <0.001
  Peripheral vascular disease (%) 5 2 <0.001
  Cholesterol-reducing therapy (%) 34 22 <0.001
  Antihypertensive therapy (%) 36 35 0.4
Laboratory assessment
  hs-CRP, mg/L 5.66±6.65 2.86±6.49 <0.001
  Total cholesterol, mmol/L 5.10±1.14 5.22±1.14 0.04
  LDL cholesterol, mmol/L 3.00±0.98 3.11±0.98 0.05
  HDL cholesterol, mmol/L 1.44±0.46 1.50±0.44 0.01
  Triglycerides, mmol/L 1.56±0.84 1.52±0.89 0.3
  GFR, mL/min per 1.73 m2 91±21 80±19 <0.001
  Glucose, mmol/L 5.30±1.56 5.31±1.83 0.9
Data are means±SD or percentage. COPD indicates chronic obstructive 
pulmonary disease; FEV
1
, forced expiratory lung volume in 1 second; FVC, forced 
vital capacity; GFR, glomerular filtration rate; HDL, high-density lipoprotein; hs-
CRP, high-sensitivity C-reactive protein; and LDL, low-density lipoprotein.
Table 2. Hemodynamic Characteristics of Patients With COPD 
and Controls
Variable
COPD
 n=458
Controls
 n=1657 P Value
Systolic BP, mm Hg 145±18 140±18 <0.001
Diastolic BP, mm Hg 82±11 81±10 0.3
Mean arterial pressure, mm Hg 97±11 96±11 0.6
Pulse pressure, mm Hg 64±16 59±15 <0.001
Heart rate, bpm 75±12 70±12 <0.001
Aortic PWV, m/s 10.33±2.48 9.15±2.22 <0.001
Adjusted aortic PWV, m/s* 9.95±2.54 9.27±2.41 <0.001
Augmentation index (%) 27±10 25±10 <0.001
Adjusted augmentation index (%)† 28±10 25±9 <0.001
Carotid IMT, mm 0.85±0.19 0.70±0.14 <0.001
Carotid IMT, mm‡ 0.83±0.19 0.74±0.21 <0.001
Data are means±SD. BP indicates blood pressure; COPD, chronic obstructive 
pulmonary disease; IMT, intima–media thickness; and PWV, pulse wave velocity.
*Aortic pulse wave velocity adjusted for heart rate, mean arterial pressure, 
and study site.
†Augmentation index adjusted for height, heart rate, and study site.
‡Carotid intima–media thickness adjusted for systolic blood pressure and 
study site.
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and ex-smokers had increased AIx compared with controls 
(29±7% versus 25±9%, P<0.001 and 27±7% versus 25±9%, 
P<0.001, respectively). Furthermore, there were no differ-
ences in aPWV or CIMT in patients with COPD according 
to smoking status. In patients with COPD, total pack years 
smoked (47±27 years) was not associated with aPWV, AIx, or 
CIMT after adjustment for physiological confounders.
Impact of COPD
A diagnosis of COPD was positively associated with aPWV, 
AIx, and CIMT, and the associations remained after adjust-
ment for physiological confounders and cardiovascular 
risk factors (Table 4). Moreover, patients with COPD were 
2× to 5× more likely to have increased cardiovascular risk 
defined by thresholds of aPWV >10 m/s and CIMT >0.90 
mm,15 odds ratio: 2.29 (95% confidence interval: 1.74, 3.01) 
and odds ratio: 5.83 (95% confidence interval: 3.15, 10.77) 
respectively, after adjustment for those variables remaining 
independently associated with each vascular biomarker in 
regression analyses.
COPD Severity and Vascular Biomarkers
A total of 427 patients with COPD had sufficient data to clas-
sify into BODE Index quartiles, Table S3. Patients with COPD 
in the fourth quartile had higher aPWV than all other quartiles 
(Figure S1), even after adjustment for respiratory medication 
and peripheral oxygen saturations differences, but in contrast, 
AIx and CIMT were similar across quartiles. Furthermore, 
the BODE Index score was positively associated with aPWV, 
independently of physiological confounders and cardiovascu-
lar risk factors, Table S4. However, no associations between 
exacerbations and vascular biomarkers were observed.
Discussion
We have shown that surrogate markers of cardiovascular risk 
are increased in patients with COPD compared with age-, 
sex-, and BMI-matched controls, independently of known car-
diovascular risk factors, including smoking, and physiological 
confounders. In patients with COPD, a positive relationship 
between disease severity and specifically arterial stiffness 
was observed but not for wave reflections or subclinical 
Figure. Comparison of surrogate cardiovascular risk markers 
(A) aortic pulse wave velocity, (B) augmentation index, and 
(C) carotid intima–media thickness (CIMT) between patients 
with chronic obstructive pulmonary disease (COPD) and 
controls. Bars represent mean values, error bars represent 95% 
confidence intervals. Aortic pulse wave velocity is adjusted for 
heart rate, mean arterial pressure, and study site. Augmentation 
index is adjusted for height, heart rate, and study site. CIMT is 
adjusted for systolic blood pressure and study site. ***P<0.001.
Table 3.  Demographic and Hemodynamic Characteristics of 
Patients With COPD and Controls Who Are Current/Ex-Smokers
Variable
COPD
 n=458
Controls
 n=718 P Value
Age, y 67±8 67±8 0.9
Male, n (%) 264 (58%) 502 (70%) <0.001
Body mass index, kg/m2 27.68±5.70 27.83±4.15 0.7
Systolic BP, mm Hg 145±18 141±17 <0.001
Diastolic BP, mm Hg 82±11 82±11 0.9
Mean arterial pressure, mm Hg 97±11 97±11 0.4
Pulse pressure, mm Hg 64±16 59±14 <0.001
Heart rate, bpm 75±12 70±12 <0.001
Adjusted aortic PWV, m/s* 10.13±2.68 9.29±2.51 <0.001
Adjusted augmentation index (%)† 28±10 24±9 <0.001
Carotid IMT, mm‡ 0.84±0.19 0.77±0.21 0.007
Data are means±SD. BP indicates blood pressure; COPD, chronic obstructive 
pulmonary disease; IMT, intima–media thickness; and PWV, pulse wave velocity.
*Aortic pulse wave velocity adjusted for sex, heart rate, mean arterial 
pressure, and study site.
†Augmentation index adjusted for sex, height, heart rate, and study site.
‡Carotid intima–media thickness adjusted for systolic blood pressure and 
study site.
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atherosclerosis. Interestingly, smoking quantified by total 
pack years smoked was not independently associated with 
vascular biomarkers within patients with COPD.
Aortic stiffness, defined by aPWV, was +0.7 m/s higher 
in patients with COPD compared with controls. This is a 
smaller difference than previously reported,7 which may be 
because of our much larger group of unselected controls, and 
full adjustment for physiological confounders. Nevertheless, 
it is still a clinically important difference, suggesting acceler-
ated vascular aging in patients with COPD, because a recent 
meta-analysis reported that a +1-m/s difference in aPWV is 
associated with ≈15% increased risk of cardiovascular events 
and mortality.17 Importantly, we have demonstrated that the 
presence of COPD was independently associated with aPWV 
and that patients with COPD were twice as likely as controls to 
have increased arterial stiffness, even after accounting for the 
potential influence of confounding factors in a fully adjusted 
model. The lack of difference in aPWV in different groups of 
patients with COPD stratified by smoking status together with 
the lack of any independent association between aPWV and 
total pack years smoked is in keeping with published data in 
COPD.18
For the first time, we have demonstrated that a diagnosis 
of COPD had a stronger impact on AIx than did smoking 
and other cardiovascular risk factors. Also, the larger dif-
ference in AIx in those patients with COPD versus controls 
aged ≤55 years is likely to be clinically important because 
it suggests increased cardiovascular risk even in younger 
patients with COPD.12 In a previous smaller study, Mills et 
al19 observed an increase in augmentation pressure rather 
than AIx in patients with COPD compared with healthy 
controls who were not on any regular medication and had 
no other comorbidities, matched for smoking. Janner et 
al8 examined a general population and found that subjects 
with obstructive spirometry had higher AIx, but, crucially, 
smoking confounded this association. Although patients 
with COPD who were current smokers had increased AIx 
compared with COPD ex-smokers in our study, COPD 
per se was associated with increased AIx compared with 
controls, irrespective of smoking status, and there was no 
relationship with total pack years smoked. A further con-
sideration is that AIx is influenced by dynamic changes 
in peripheral vascular resistance. We did not assess resis-
tance in our study, but Casiglia et al20 found that patients 
with COPD versus controls had increased calf blood flow 
evaluated by venous occlusion plethysmography, as well 
as lower leg vascular resistance, but did not report total 
peripheral resistance. If systemic resistance was lower in 
our patients with COPD, this would be expected to reduce 
AIx, therefore reducing the observed difference between 
them and controls.
Further novel findings of the current study include greater 
CIMT in patients with COPD versus controls, together with 
the independent association between COPD and higher 
CIMT, and our finding that patients with COPD are 5× more 
likely than controls to have increased CIMT, independent of 
confounding factors. The Kuopio Ischaemic Heart Disease 
Study indicates that even a +0.1-mm increase in CIMT is 
associated with +11% risk of myocardial infarction, sug-
gesting that the differences between patients and controls 
seen in our study are likely to be clinically important.21 In 
addition, in patients with COPD in the current study, CIMT 
was similar between current and ex-smokers, and there was 
no association between CIMT and total pack years smoked. 
Taken together, these observations suggest that the presence 
Table 4. Variables Associated With aPWV, AIx, and CIMT
 β P Value
Aortic pulse wave velocity
  Adjusted R 2=0.36, P<0.001   
  Age, y 0.37 <0.001
  Mean arterial pressure, mm Hg 0.28 <0.001
  COPD (yes/no) 0.16 <0.001
  Heart rate, bpm 0.16 <0.001
  Body mass index, kg/m2 0.08 <0.001
  Peripheral vascular disease (yes/no) 0.09 <0.001
  Antihypertensive therapy (yes/no) 0.06 0.004
  Triglycerides, mmol/L 0.06 0.01
  Female gender −0.05 0.02
  Diabetes mellitus (yes/no) 0.05 0.03
Augmentation index
  Adjusted R 2=0.51, P<0.001   
  Heart rate, bpm −0.54 <0.001
  Female gender 0.29 <0.001
  Height, cm −0.18 <0.001
  Age, y 0.17 <0.001
  COPD (yes/no) 0.16 <0.001
  Smoker (yes/no) 0.07 0.001
  Diabetes mellitus (yes/no) −0.04 0.03
  Total cholesterol, mmol/L 0.04 0.03
  Glucose, mmol/L −0.04 0.04
Carotid intima–media thickness
  Adjusted R 2=0.24, P<0.001   
  COPD (yes/no) 0.30 <0.001
  Systolic blood pressure, mm Hg 0.28 <0.001
  Diastolic blood pressure, mm Hg −0.22 0.001
  Age, y 0.12 0.007
Variables that were not independently associated with aPWV: glucose 
(mmol/L), cholesterol-reducing therapy (yes/no), total cholesterol (mmol/L), 
angina (yes/no), smoker (yes/no), myocardial infarction (yes/no), stroke (yes/
no). Variables that were not independently associated with AIx: cholesterol-
reducing therapy (yes/no), total cholesterol (mmol/L), angina (yes/no), myocardial 
infarction (yes/no), stroke (yes/no), peripheral vascular disease (yes/no), 
triglycerides (mmol/L), antihypertensive therapy (yes/no). Variables that were 
not independently associated with CIMT: glucose (mmol/L), cholesterol-reducing 
therapy (yes/no), total cholesterol (mmol/L), angina (yes/no), smoker (yes/no), 
myocardial infarction (yes/no), stroke (yes/no), peripheral vascular disease (yes/
no), triglycerides (mmol/L), female gender, body mass index (kg/m2), diabetes 
mellitus (yes/no). aPWV indicates aortic pulse wave velocity; AIx, augmentation 
index; CIMT, carotid intima–media thickness; and COPD, chronic obstructive 
pulmonary disease.
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of COPD indicates a vulnerability to smoke injury rather than 
magnitude of smoke exposure.
There are few previous studies of CIMT relevant to 
COPD to enable direct comparison with our data. In the 
MESA study (Multi-Ethnic Study of Atherosclerosis), CIMT 
was associated with decrements in forced expiratory lung 
volume in 1 second.22 In a study of 200 patients with COPD, 
CIMT >0.9 mm and cardiac infarction injury score >20 were 
used to define cardiovascular comorbidity, but the study 
did not include controls or patients with CIMT ≤0.9 mm.23 
Interestingly, common genetic loci implicated in determining 
lung function also influence CIMT,24 suggesting that shared 
genetic factors may influence susceptibility to lung and vas-
cular damage.
The independent association between the presence of 
COPD and arterial stiffness, wave reflections, and CIMT 
implies that COPD should be considered an independent 
cardiovascular risk factor, and further studies are necessary 
to robustly calculate its predictive value for cardiovascular 
events. This is in keeping with findings by Finkelstein et al25 
who reported that COPD increased the likelihood of CVD, 
adjusted for comorbidities and socioeconomic factors includ-
ing tobacco use. Interestingly, in the current study, a higher 
proportion of patients with COPD than controls reported tak-
ing cholesterol-reducing therapies (reflected in their lower 
lipid profile levels), suggesting that consideration of cardio-
vascular risk reduction in patients with COPD had already 
occurred. Patients with COPD also had higher glomerular 
filtration rate values although this likely represents lower 
fat-free muscle mass for equivalent BMI, rather than better 
renal function.26 However, patients with COPD had increased 
systolic blood pressure compared with controls despite com-
parable rates of antihypertensive therapy between groups. 
Assuming equivalent compliance, this suggests that more 
intense treatment of systolic blood pressure may be required 
in patients with COPD to achieve the same reduction in blood 
pressure compared with controls and is an area that requires 
further research. Patients with COPD also had a higher preva-
lence of self-reported cardiovascular comorbidities compared 
with controls. However, prevalence may be even higher when 
assessed objectively. For example, peripheral vascular disease 
prevalence was 8.8% when assessed by ankle–brachial index 
in patients with COPD in a recent European cohort (compared 
with 5% self-reported in our study) although two thirds of 
these subjects did not report peripheral vascular disease in 
their medical history.27
Why we observed a relationship between COPD sever-
ity defined by the BODE Index10 and aPWV, but not AIx, 
or CIMT highlights the different nature of these vascular 
parameters. Indeed, the novel association between aPWV 
and the BODE Index score suggests a complex interaction 
between vascular stiffness with the score’s composite vari-
ables of lung function, symptoms, and physical capacity. 
BODE may also enhance cardiovascular risk stratification 
in patients with COPD because its relationship with aPWV 
was independent of traditional cardiovascular risk factors. 
One potential explanation for the relationship between 
COPD severity and specifically aPWV is a shared patho-
logical mechanism of degradation of elastin fibers from the 
lungs and large arteries because elastin is known to con-
fer elasticity to both organs. A previous study showed that 
patients with COPD had excessive cutaneous elastin loss, 
which related to increased cutaneous elastolytic activity, 
emphysema severity, and arterial stiffness.28 Therefore, the 
possibility of a systemic elastin degradation pathology con-
tributing to the pulmonary and vascular features associated 
with COPD is raised28 although other mechanisms, such as 
the effects of hypoxia, may also be important. Notably, an 
inverse association between peripheral oxygen saturations 
and aPWV in patients with COPD has been observed.29 
In contrast to aPWV, AIx is a composite measure of wave 
reflections and arterial stiffness, and CIMT is a complex 
measure of subclinical atherosclerosis determined by 
intima thickening and medial hypertrophy driven by pulse 
pressure. These 2 vascular markers may be elevated in 
patients with COPD but may not be mechanistically linked 
to the severity of COPD itself and do not add value to the 
Framingham risk score, unlike aPWV.6,30
The strengths of our study are its size, inclusion of con-
trols that were not selected to be healthy, and adjustment for 
known physiological confounders and established cardiovas-
cular risk factors. Moreover, we included a high percentage 
of smokers and ex-smokers in our control group, emphasiz-
ing the influence of COPD per se on these vascular biomark-
ers. The main limitation is its cross-sectional nature, which 
does not permit any assessment of causality. A further limi-
tation is that we were unable to adjust for factors that were 
not measured, such as physical activity levels, or those unique 
to patients with COPD, such as respiratory medications. The 
potential influence on our results of medications, such as 
inhaled β-agonists, should be considered. β-agonists are asso-
ciated with increased risk of cardiovascular events,31 but they 
also reduce wave reflections, mediated, in part, by their effect 
on the nitric oxide pathway.32 The long-term influence of such 
medications on the vascular health of patients with COPD is 
thus difficult to gauge, but trial data have showed no beneficial 
effect on aPWV, of 6-month treatment of combined inhaled 
corticosteroid and long-acting β-agonist versus placebo.33
Perspectives
We have demonstrated that patients with COPD compared 
with controls have elevated arterial stiffness, wave reflections, 
and subclinical atherosclerosis. Moreover, the presence of 
COPD was associated with aPWV, AIx, and CIMT, indepen-
dently of traditional cardiovascular risk factors, and arterial 
stiffness measured by aPWV was positively associated with 
COPD severity, defined by the BODE Index score. These data 
support the notion that the presence of COPD is an indepen-
dent risk factor for CVD, and further studies are needed to 
determine the impact of the presence of COPD in vascular 
risk models. In addition, because these vascular biomarkers 
are plausible mechanisms mediating increased cardiovascular 
risk in COPD, trials of novel therapies targeted toward these 
surrogate risk markers are required.
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What Is New?
•	We have shown for the first time that patients with chronic obstructive 
pulmonary disease (COPD) have elevated levels of arterial stiffness, wave 
reflections, and subclinical atherosclerosis independently of potential 
confounders, including smoking. Furthermore, arterial stiffness was 
associated with COPD severity, defined by the BODE Index (body mass 
index [B], degree of airflow obstruction [O], and functional dyspnea [D], 
and exercise capacity [E] as assessed by the 6-minute walk test) score.
What Is Relevant?
•	Patients with COPD have stiffer arteries, increased subclinical ath-
erosclerosis, and higher systolic blood pressure compared with age-, 
gender-, body mass index–matched controls despite more patients with 
COPD being on cholesterol-reducing therapies and equivalent rates of 
antihypertensive therapies between groups.
Summary
This large case-controlled study showed that surrogate markers 
of cardiovascular risk were increased in patients with COPD com-
pared with controls independently of confounding factors.
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Expanded methods: 
 
Vascular biomarkers and laboratory assessments: 
All studies were conducted in a quiet, temperature-controlled room. In all individuals, 
brachial blood pressure was recorded after 15-minutes of rest (seated prior to 
augmentation index (AIx) measurement and supine prior to aortic pulse wave velocity 
measurement (aPWV)), using a validated oscillometric device (HEM 750CP; Omron 
Corporation, Japan). Blood pressure was measured in the non-dominant arm and three 
measurements taken, with a 1-minute interval between them. The average of the 2nd 
and 3rd reading was recorded and used in analysis. If the difference between the 2nd 
and 3rd exceeded 5mm Hg, further readings were taken. Assessments of vascular 
biomarkers (AIx, aPWV and carotid intima-media thickness (CIMT)) for chronic 
obstructive pulmonary disease (COPD) patients were performed after a 12-hour 
period without inhaled medications, with the exception of short acting beta agonist 
use allowed no less than 6-hours before assessments if needed for symptomatic relief.  
Trained investigators performed all vascular assessments in duplicate, and mean 
values were used in subsequent analysis. The within- and between-observer 
measurement reproducibility values were in agreement with our previously published 
data.1,2 
Serum samples were analyzed in accredited laboratories. The estimated glomerular 
filtration rate (eGFR) was calculated as per the Modified Diet and Renal Disease 
equation.3 
 
COPD severity: 
The BODE Index score (0-10) is a multidimensional COPD severity classification, 
comprising of four weighted variables: Body mass index (kg/m2), Obstruction 
(Forced Expiratory Lung Volume in 1 second % predicted), Dyspnea (modified MRC 
score (0-4)), and Exercise capacity (6-minute walk distance (metres)) that robustly 
predicts mortality in COPD.4 COPD patients in the study were stratified into BODE 
quartiles (Q1: 0-2, Q2: 3-4, Q3: 5-6, Q4: 7-10), to evaluate for differences in aPWV, 
AIx and CIMT across quartiles. Additionally, the relationship between reported 
exacerbations (defined as worsening respiratory symptoms requiring treatment with 
antibiotics and/or steroids) and these vascular biomarkers was examined. 
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Table S1: Demographic and haemodynamic characteristics of COPD patients 
and controls without known cardiovascular comorbidity. 
Data are means±(standard deviation (SD)) or percentage. Subjects with any known 
cardiovascular comorbidity (angina, myocardial infarction, stroke, peripheral vascular 
disease, diabetes mellitus, antihypertensive treatment, cholesterol-reducing therapy) 
were excluded from analysis. BP=blood pressure, PWV= pulse wave velocity, 
IMT=intima-media thickness. *Aortic pulse wave velocity adjusted for gender, heart 
rate, mean arterial pressure and study site. †Augmentation index adjusted for gender, 
height, heart rate and study site. ‡Carotid intima media thickness adjusted for systolic 
blood pressure and study site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable COPD n=190 
Controls 
n=660 p-value 
Age (years) 66±8 65±9 0.8 
Male n (%) 100 (53%) 405 (61%) 0.02 
Body mass index (kg/m2) 26.08±5.78 26.55±3.89 0.2 
Systolic BP (mmHg) 143±19 140±18 <0.001 
Diastolic BP (mmHg) 81±10 82±10 0.7 
Mean arterial pressure (mmHg) 96±11 96±11 0.8 
Pulse pressure (mmHg) 62±16 56±14 <0.001 
Heart rate (bpm) 75±12 71±12 <0.001 
Adjusted Aortic PWV (m/s)* 9.48±2.34 8.87±2.06 0.003 
Adjusted Augmentation Index (%)†  28±9 24±8 <0.001 
Carotid IMT (mm)‡ 0.79±0.20 0.73±0.20 0.007 
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Table S2: Demographic and haemodynamic characteristics in COPD patients 
and controls stratified by smoking status 
 
Variable Never-Smoker Ex-Smoker 
 
Smoker 
 
p-value 
Controls 
Number (%) 939 (57%) 647 (39%) 71 (4%) - 
Age (years) 68±8 68±8 65±10 0.01 
Male n (%) 476 (51%) 443 (68%) 59 (83%) <0.001 
BMI (kg/m2) 27.00±4.42 27.95±4.21 26.75±3.41 <0.001 
FEV1 (L) 2.47±0.83 2.52±0.84 2.62±0.80 0.3 
FEV1 (%) 102±17 98±18 92±17 <0.001 
HR (bpm) 71±12 70±12 73±12 0.1 
SBP (mmHg) 140±18 141±17 138±21 0.1 
DBP (mmHg) 80±10 82±10 81±11 0.08 
MAP (mmHg) 96±11 97±10 95±12 0.006 
aPWV (m/s)* 9.22±1.87 9.04±1.89 9.49±1.86 0.07 
AIx (%)† 25±7 25±07 26±7 0.07 
COPD patients 
Number (%) 0 307 (67%) 151 (33%) - 
Age (years) - 69±8 64±8 <0.001 
Male n (%) - 181 (59%) 83 (55%) 0.2 
BMI (kg/m2) - 28.09±5.48 26.87±6.07 0.04 
FEV1 (L) - 1.31±0.51 1.39±0.56 0.1 
FEV1 (%) - 53±16 53±16 0.8 
HR (bpm) - 74±12 75±12 0.53 
SBP (mmHg) - 147±18 143±19 0.03 
DBP (mmHg) - 82±11 81±11 0.8 
MAP (mmHg)  97±11 96±11 0.09 
aPWV (m/s)* - 10.34±2.07 10.26±1.76 0.7 
AIx (%)† - 27±7 29±8 0.02 
CIMT‡ (mm) - 0.86±0.17 0.85±0.18 0.6 
Data are means±SD or percentage. BMI=body mass index, FEV1=Forced expiratory 
lung volume in 1 second, HR= heart rate, SBP=systolic blood pressure, 
DBP=diastolic blood pressure, MAP=mean arterial pressure, aPWV= aortic pulse 
wave velocity, AIx= augmentation index, CIMT=Carotid intima-media thickness. 
*Aortic pulse wave velocity adjusted for age, gender, body mass index, heart rate, 
mean arterial pressure and study site. †Augmentation index adjusted for age, gender, 
height, heart rate and study site. ‡Carotid intima-media thickness adjusted for age, 
systolic blood pressure and study site. 
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Table S3: Demographic and vascular characteristics of COPD patients classified 
by BODE Index score quartiles 
Data are means±SD or percentage. BMI=Body mass index, ICS+LABA=Combined 
inhaled corticosteroid and long acting beta agonist inhaler, ICS=inhaled corticosteroid 
inhaler, LABA=long acting beta agonist inhaler, LAMA=long acting muscarinic 
antagonist, PVD=peripheral vascular disease, SBP=systolic blood pressure, 
DBP=diastolic blood pressure, MAP=mean arterial pressure, aPWV=aortic pulse wave 
velocity, IMT=intima media thickness. *adjusted for heart rate, mean arterial pressure, 
study site, LAMA use, ICS+LABA use and oxygen saturations †=adjusted for heart rate, 
height and study site, ‡=adjusted for study site. 
Variable 
Q1 
0-2 
n=197 
Q2 
3-4 
n=95 
Q3 
5-6 
n=87 
Q4 
7-10 
n=48 
p-
value 
Age (years) 67±8 67±8 67±8 67±8 0.8 
Male n (%) 125 (63%) 45 (47%) 50 (57%) 29 (60%) 0.07 
BMI (kg/m2) 27.62±4.19 27.60±5.48 28.08±6.72 26.68±7.64 0.6 
Current smoker n (%) 60 (30%) 33 (35%) 33 (38%) 16 (33%) 
0.7 
Ex-smoker n (%) 137 (70%) 62 (65%) 54 (62%) 32 (67%) 
Total pack years 47±26 48±31 46±25 54±27 0.4 
Oxygen saturations (%) 97±2 96±2 95±3 96±2 <0.001 
  Respiratory Medication 
ICS+LABA (%) 49 62 71 79 <0.001 
ICS (%) 7 8 8 6 0.9 
LABA (%) 7 10 10 8 0.8 
LAMA (%) 49 72 76 75 <0.001 
  Cardiovascular medical history 
Angina (%) 6 19 6 13 0.02 
Myocardial infarction (%) 5 12 6 10 0.2 
Stroke (%) 9 10 6 7 0.7 
Diabetes mellitus (%) 12 19 11 15 0.5 
PVD (%) 7 8 1 6 0.2 
Cholesterol-reducing therapy (%) 33 47 33 30 0.1 
Antihypertensive therapy (%) 39 39 32 36 0.7 
  Haemodynamic assessment 
SBP (mmHg) 146±18 142±17 148±20 140±19 0.02 
DBP (mmHg) 82±10 81±11 83±11 78±13 0.08 
MAP (mmHg) 103±11 101±11 104±12 98±13 0.03 
Pulse pressure (mmHg) 65±16 64±14 63±14 64±16 0.9 
Heart rate (bpm) 68±11 71±10 71±12 76±11 <0.001 
aPWV (m/s) 9.99±2.52 10.17±2.22 10.47±2.42 11.37±2.79 <0.001 
aPWV (m/s)* 10.01±2.46 10.21±2.36 10.37±2.38 11.39±2.43 0.01 
Augmentation index (%) 28+10 28±10 28±11 24±9 0.1 
Augmentation index (%)† 27±7 27±7 28±7 27±7 0.8 
Carotid IMT (mm) 0.86±0.18 0.86±20 0.83±18 0.84±0.21 0.6 
Carotid IMT (mm)‡ 0.86±0.19 0.86±0.19 0.87±0.18 0.84±0.19 0.5 
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Table S4: BODE Index association with aortic pulse wave velocity in COPD 
patients 
 
 
Aortic pulse wave velocity Beta p-value 
Adjusted R2=0.41, P<0.001   
Age (years) 0.46 <0.001 
Mean arterial pressure (mmHg) 0.21 <0.001 
Heart rate (bpm) 0.16 <0.001 
Glucose (mmol/L) 0.12 0.006 
BODE Index (0-10) 0.10 0.01 
PVD (yes/no) 0.09 0.03 
Body mass index (kg/m2) 0.09 0.04 
PVD=Peripheral vascular disease. Variables that were not independently associated 
with aortic pulse wave velocity: cholesterol-reducing therapy (yes/no), total 
cholesterol (mmol/L), triglycerides (mmol/L), smoker (yes/no), total pack years 
smoked, diabetes mellitus (yes/no), angina (yes/no), myocardial infarction (yes/no), 
stroke (yes/no), antihypertensive therapy (yes/no). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 8	
 
 
Figure S1: Aortic pulse wave velocity stratified by BODE Index quartiles of COPD 
patients.  
***P<0.001 4th vs 1st quartile, †P=0.006 4th vs 2nd quartile, ‡P=0.02 4th vs 3rd quartile. 
Bars represent mean values, error bars represent 95% confidence intervals. Aortic 
pulse wave velocity adjusted for heart rate, mean arterial pressure, study site, long acting 
muscarinic antagonist use, combined long acting beta agonist/inhaled corticosteroid use, 
peripheral oxygen saturations. 
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